Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 24kWORD 22k
30 April 2019
E-001049/2019(ASW)
Answer given by Vice-President Katainen on behalf of the European Commission
Question reference: E-001049/2019

The Commission notes that although medicines authorised at EU level can be placed on the market in all Member States, this is not always the case, as placing on the market depends on the decision of companies and on pricing and reimbursement decisions.

Pricing policies for medicinal products are Member States’ competence. However, the Commission promotes the exchange of information among Member States on their pricing policies, for example through the European medicine price database (EURIPID)(1) and projects by the Organisation for Economic Cooperation and Development (OECD)(2). The Commission also facilitates the exchange of best practices and knowledge among Member States through a network of competent authorities(3).

As part of its competition policy, the Commission monitors pharmaceutical markets and investigates, where appropriate, possible breaches of EU competition rules. In addition, the Commission supports national competition authorities in Europe that can investigate possible breaches of EU competition rules, including as regards excessive pricing(4).

(1)https://www.euripid.eu/aboutus
(2)http://www.oecd.org/els/health-systems/pharmaceuticals.htm
(3)Known as the Network of Competent Authorities on Pricing and Reimbursement (CAPR)
(4)Report ‘European competition authorities working together for affordable and innovative medicines’ http://ec.europa.eu/competition/sectors/pharmaceuticals/report2019/index.html

Last updated: 2 May 2019Legal notice